Santhera Pharmaceuticals Holding AG Logo

Santhera Pharmaceuticals Holding AG

Develops innovative medicines for rare neuromuscular and mitochondrial disorders.

SANN | SW

Overview

Corporate Details

ISIN(s):
CH1276028821
LEI:
54930035HAOFTTQH0U85
Country:
Switzerland
Address:
HOHENRAINSTRASSE 24, 4133 PRATTELN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for patients with rare diseases. The company targets conditions with high unmet medical needs, primarily in the area of rare neuromuscular and mitochondrial disorders. Santhera's mission is to provide treatment options for diseases that severely impact the lives of affected children and adults and currently have limited or no available therapies. Its development efforts include advanced treatments such as gene therapy for conditions like LAMA2-deficient congenital muscular dystrophy (CMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Santhera Pharmaceuticals Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Santhera Pharmaceuticals Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Santhera Pharmaceuticals Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-01-11 N/A Non-Executive member Buy None 42,600.00 CHF
2022-01-10 N/A Executive member Buy None 14,420.00 CHF
2022-01-05 N/A Executive member Buy None 37,000.00 CHF

Peer Companies

Perseus Proteomics Inc. Logo
Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.
Japan
4882
Personalis, Inc. Logo
Cancer genomics & liquid biopsy for early recurrence detection & guiding precision therapies.
United States of America
PSNL
Perspective Therapeutics, Inc. Logo
Developing targeted alpha radiotherapies using lead-212 to image and treat solid tumors.
United States of America
CATX
PharmAbcine Inc. Logo
Develops antibody therapies for cancer, eye diseases, and vascular-related disorders.
South Korea
208340
Pharma Foods International Co., Ltd. Logo
Researches and sells functional ingredients and direct-to-consumer health & beauty products.
Japan
2929
PharmaLundensis AB Logo
Develops treatments for heavy metal toxicity and serious respiratory illnesses.
Sweden
PHAL
Pharma Mar S.A. Logo
Develops and commercializes marine-derived oncology treatments for rare cancers.
Spain
PHM
Pharmanutra Logo
Researches and markets nutritional supplements & medical devices for all ages.
Italy
PHN
PHARMARESEARCH BIO Co., Ltd. Logo
A global biopharma firm creating regenerative medicine, pharmaceuticals, devices, and cosmetics.
South Korea
217950
PharmaResearch Co., Ltd. Logo
Develops regenerative medicine, devices & cosmetics using marine biotechnology.
South Korea
214450

Talk to a Data Expert

Have a question? We'll get back to you promptly.